Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Radiology Department, Hotchkiss Brain Institute, Calgary, Alberta, Canada; Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital of Basel, Basel, Switzerland.
World Neurosurg. 2020 Sep;141:e677-e685. doi: 10.1016/j.wneu.2020.05.277. Epub 2020 Jun 19.
Therapeutic hypothermia (TH) offers cerebral protection following ischemic stroke and may improve outcomes in conjunction with decompressive hemicraniectomy (DHC). We aimed to assess the effectiveness of TH in patients with malignant ischemic stroke and DHC.
We performed a meta-analysis in patients with malignant ischemic stroke undergoing DHC comparing TH versus normothermia in studies published up to August 2019. Included studies had ≥10 adults with acute ischemic stroke. Primary outcome was functional independence, and secondary outcomes included complications. Effect size was pooled and described by relative risk (RR) ratios and 95% confidence intervals (CIs).
Five studies (n = 269 patients; n = 130 TH, n = 139 controls) were included, 4 of which were prospective (n = 2 randomized controlled trials). Median achieved body temperature of TH was 33.6°C (range 33°C-35°C). Median modified Rankin Scale at the study completion was similar between TH and controls (RR 1.08, 95% CI 0.56-2.07, P = 0.8). Three studies reported individual patient modified Rankin Scale outcomes demonstrated a shift toward worse outcomes with TH (unadjusted common odds ratio 1.74; 95% CI 1.05-2.88, P = 0.01). Overall complications were similar between groups (RR 1.20, 95% CI 0.70-2.05, random effects P = 0.5). A suggestion of higher mortality was seen in TH (RR 1.50, 95% CI 0.97-2.32, P = 0.07).
Clinical and functional outcomes were not overall different between patients undergoing systemic TH and controls following DHC despite the shift toward worse outcomes with TH observed in some studies.
治疗性低温(TH)可提供缺血性中风后的脑保护,并可能与减压性半脑切除术(DHC)联合改善预后。我们旨在评估在接受 DHC 的恶性缺血性中风患者中 TH 的有效性。
我们对截至 2019 年 8 月发表的研究进行了一项荟萃分析,比较了 DHC 中恶性缺血性中风患者的 TH 与正常体温。纳入的研究均有≥10 名急性缺血性中风成人患者。主要结局为功能独立性,次要结局包括并发症。通过相对风险(RR)比和 95%置信区间(CI)来汇总和描述效应大小。
共纳入 5 项研究(n=269 例患者;n=130 例 TH,n=139 例对照组),其中 4 项为前瞻性研究(n=2 项随机对照试验)。TH 的平均达到体温为 33.6°C(范围 33°C-35°C)。研究完成时,TH 组和对照组的改良 Rankin 量表中位数相似(RR 1.08,95%CI 0.56-2.07,P=0.8)。3 项研究报告了个别患者改良 Rankin 量表结果,表明 TH 组的结果向更差的方向转变(未调整的共同优势比 1.74;95%CI 1.05-2.88,P=0.01)。两组的总体并发症相似(RR 1.20,95%CI 0.70-2.05,随机效应 P=0.5)。TH 组的死亡率似乎更高(RR 1.50,95%CI 0.97-2.32,P=0.07)。
尽管一些研究表明 TH 组的结果更差,但 DHC 后接受全身 TH 的患者与对照组的临床和功能结局总体上并无不同。